1. Long-term relapse-free survival enabled by integrating targeted antibacteria in antitumor treatment
- Author
-
Yuanlin Wang, Yaqian Han, Chenhui Yang, Tiancheng Bai, Chenggang Zhang, Zhaotong Wang, Ye Sun, Ying Hu, Flemming Besenbacher, Chunying Chen, and Miao Yu
- Subjects
Science - Abstract
Abstract The role of tumor-resident intracellular microbiota (TRIM) in carcinogenesis has sparked enormous interest. Nevertheless, the impact of TRIM-targeted antibacteria on tumor inhibition and immune regulation in the tumor microenvironment (TME) remains unexplored. Herein, we report long-term relapse-free survival by coordinating antibacteria with antitumor treatment, addressing the aggravated immunosuppression and tumor overgrowth induced by TRIM using breast and prostate cancer models. Combining Ag+ release with a Fenton-like reaction and photothermal conversion, simultaneous bacteria killing and multimodal antitumor therapy are enabled by a single agent. Free of immune-stimulating drugs, the agent restores antitumor immune surveillance and activates immunological responses. Secondary inoculation and distal tumor analysis confirm lasting immunological memory and systemic immune responses. A relapse-free survival of >700 days is achieved. This work unravels the crucial role of TRIM-targeted antibacteria in tumor inhibition and unlocks an unconventional route for immune regulation in TME and a complete cure for cancer.
- Published
- 2024
- Full Text
- View/download PDF